Navigation Links
New blood cells fight brain inflammation
Date:2/16/2014

Hyperactivity of our immune system can cause a state of chronic inflammation. If chronic, the inflammation will affect our body and result in disease. In the devastating disease multiple sclerosis, hyperactivity of immune cells called T-cells induce chronic inflammation and degeneration of the brain. Researchers at BRIC, the University of Copenhagen, have identified a new type of regulatory blood cells that can combat such hyperactive T-cells in blood from patients with multiple sclerosis. By stimulating the regulatory blood cells, the researchers significantly decreased the level of brain inflammation and disease in a biological model. The results are published in the journal Nature Medicine.

Molecule activate anti-inflammatory blood cells

The new blood cells belong to the group of our white blood cells called lymphocytes. The cells express a molecule called FoxA1 that the researchers found is responsible for the cells' development and suppressive functions.

"We knew that some unidentified blood cells were able to inhibit multiple sclerosis-like disease in mice and through gene analysis we found out, that these cells are a subset of our lymphocytes expressing the gene FoxA1. Importantly, when inserting FoxA1 into normal lymphocytes with gene therapy, we could change them to actively regulate inflammation and inhibit multiple sclerosis, explains associated professor Yawei Liu leading the experimental studies.

Activating own blood cells for treatment of disease

FoxA1 expressing lymphocytes were not known until now, and this is the first documentation of their importance in controlling multiple sclerosis. The number of people living with this devastating disease around the world has increased by 10 percent in the past five years to 2.3 million. It affects women twice more than men and no curing treatment exists. The research group headed by professor Shohreh Issazadeh-Navikas from BRIC examined blood of patients with multiple sclerosis, before and after two years of treatment with the drug interferon-beta. They found that patients who benefit from the treatment increase the number of this new blood cell type, which fight disease.

"From a therapeutic viewpoint, our findings are really interesting and we hope that they can help finding new treatment options for patients not benefiting from existing drugs, especially more chronic and progressive multiple sclerosis patients. In our model, we could activate lymphocytes by chemical stimulation and gene therapy, and we are curios whether this can be a new treatment strategy", says professor Shohreh Issazadeh-Navikas.

And this is exactly what the research group will focus on at next stage of their research. They have already started to test whether the new FoxA1-lymphocytes can prevent degradation of the nerve cell's myelin layer and brain degeneration in a model of progressive multiple sclerosis. Besides multiple sclerosis, knowledge on how to prevent chronic inflammation will also be valuable for other autoimmune diseases like type 1 diabetes, inflammatory bowel disease and rheumatoid arthritis, where inflammation is a major cause of the disease.


'/>"/>

Contact: Anne Rahbek-Damm
anne.rahbek@bric.ku.dk
452-128-8541
University of Copenhagen
Source:Eurekalert

Related biology news :

1. Nanoparticle pinpoints blood vessel plaques
2. In vitro innovation: Testing nanomedicine with blood cells on a microchip
3. Red alert: Body kills spontaneous blood cancers on a daily basis
4. Blood and lymphatic capillaries grown for the first time in the lab
5. UF researchers develop blood test for devastating disease of boas and pythons
6. New molecule protects brain from detrimental effects linked to diabetes and high blood sugar
7. Punctured cell membranes lead to high blood pressure
8. FAK helps tumor cells enter the bloodstream
9. Decoded: DNA of blood-sucking worm that infects worlds poor
10. Popular blood type diet debunked
11. Study breaks blood-brain barriers to understanding Alzheimers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2016)... November 29, 2016 Nearly one billion matches per ... ... DERMALOG is ... an efficient Identity Management. (PRNewsFoto/DERMALOG Identification Systems) ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ...
(Date:11/22/2016)... 2016   MedNet Solutions , an innovative SaaS-based ... clinical research, is pleased to announce that the company ... Life Sciences Awards as "Most Outstanding in eClinical ... year of recognition and growth for MedNet, which has ... iMedNet ™ , MedNet,s flagship ...
(Date:11/17/2016)... INDUSTRY, Calif. , Nov. 17, 2016  AIC announces that it has just ... servers in organizations that require high-performance scale-out plus high speed data transfer storage solutions. ... ... ... Setting up a ...
Breaking Biology News(10 mins):
(Date:12/5/2016)... 2016 Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced that data on ... Alzheimer,s disease will be presented at the 2016 Clinical ... 9, 2016 in San Diego . ... simple and complex measures of activities of daily living ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... one of the nation’s premier cannabis technology and application experts, Chip Baker. Chip ... of Cultivate Colorado. Over the past 30 years, Chip Baker other industry veterans ...
(Date:12/5/2016)... 2016  Renova™ Therapeutics, a biotechnology company developing ... other chronic diseases, announced that Catherine Bovenizer ... Financial Officer (CFO), effective today. Ms. ... experience in financial management for a variety of ... Most recently, Ms. Bovenizer was the Vice President ...
(Date:12/5/2016)... WOODCLIFF LAKE, N.J. , Dec. 5, 2016 ... its Phase 3 open-label two-year study of rufinamide, ... of the American Epilepsy Society (AES) held from ... . Analysis of final two-year safety, tolerability and ... therapy with rufinamide experienced similar safety and tolerability ...
Breaking Biology Technology: